Through the alliance, Cornell has joined the Consortium for Sequencing the Food Supply Chain, an initiative launched by IBM and Mars in early 2015.
Baheal will be the primary channel partner in China for IBM's Watson for Genomics data analytics platform.
MLL will be the first European user of Illumina's new high-throughput sequencing platform, the NovaSeq.
The collaborations aim to combine Illumina's sequencing systems with Philips' IntelliSpace Genomics platform and with IBM's Watson for Genomics, respectively.
Pfizer will become the first firm to customize IBM's Watson for Drug Development, combining its proprietary data with licensed and publicly available data.
De-identified data from the study, which will look at 10,000 samples by whole-exome sequencing, will be made available for general research use.
The partners will combine genome editing approaches with Watson's computational and machine learning methods to study drug-resistance in tumors.
The partnership provides oncology sequencing and cognitive analytics, and it offers a framework for employing Watson to explore a broader set of diagnostic opportunities.
The service provides broad access to information that may be critical for physicians in providing precision cancer treatments.
IBM is to make its Watson technology available to its employees to identify what cancer treatments might work for them, the Wall Street Journal reports.
Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.
DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.
In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.
A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.